Financials data is unavailable for this security.
View more
Year on year Prescient Therapeutics Ltd had net income fall 17.61% from a loss of 7.00m to a larger loss of 8.24m despite a 49.77% increase in revenues from 459.10k to 687.58k.
Gross margin | -- |
---|---|
Net profit margin | -1,198.14% |
Operating margin | -1,194.87% |
Return on assets | -33.97% |
---|---|
Return on equity | -37.32% |
Return on investment | -37.31% |
More ▼
Cash flow in AUDView more
In 2024, Prescient Therapeutics Ltd increased its cash reserves by 77.99%, or 4.60m. Cash Flow from Investing totalled 12.00m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 7.40m for operations while cash generated from financing totalled 18.15k.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.0224 |
---|---|
Tangible book value per share | 0.0204 |
More ▼
Balance sheet in AUDView more
Current ratio | 8.08 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0183 |
---|---|
Total debt/total capital | 0.018 |
More ▼